All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly ...

The safety and tolerability data shown here with non-step dosing, therefore, reflect the ability of the masking to mitigate ...

The company said an experimental drug to improve the delivery of anti-cancer medications to solid tumors has shown promise in ...

In preparation for later stage clinical trials, the company is conducting a formulation bridging and titration study to evaluate capsule versus tablet pharmacokinetics (PK) and explore different ...

Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of ...

Q1 2024 Earnings Call Transcript May 8, 2024 Revolution Medicines, Inc. isn’t one of the 30 most popular stocks among hedge ...

Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $-0.06698 EPS, expectations were $-0.05.

Merck (MRK) stock slipped as a Phase 3 trial for Keytruda with chemotherapy as a first-line option fails in endometrial ...

Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in ...

Markets were more subdued in April after the strong start to the year. The S&P/ASX 200 Accumulation Index was down 2.9% and ...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ...

An autologous and personalized regulatory T cell therapy is safe in patients with type 1 diabetes, but does not help preserve ...